Contribute Try STAT+ Today

In another sign of its renewed emphasis on cancer, Sanofi (SNY) said Tuesday it will partner with the University of Texas MD Anderson Cancer Center to speed oncology research and testing of its experimental cancer drugs.

The five-year alliance, whose contractual details were not disclosed by the French pharmaceutical company or the Houston academic medical center, will bring together MD Anderson’s clinical trial system with Sanofi’s pipeline of potential cancer treatments. Sanofi signaled its intention to ramp up oncology drug development earlier this year at the American Society of Clinical Oncologists’ virtual annual meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.